Solithromycin, a novel fourth-generation macrolide, isn't a suitable alternative to standard therapy of ceftriaxone plus azithromycin for treating gonorrhea, according to a study yesterday by researchers from Australia and the United States in The Lancet Infectious Diseases.
But gentamicin combined with azithromycin might be appropriate for some patients.
The European Centre for Disease Prevention and Control (ECDC) released a new Zika risk assessment today, concluding that, while transmission has slowed in the Americas, the virus is widespread in Asia.
The assessment was conducted, in part, to update travel guidelines for Europeans visiting a country with endemic Zika or experiencing an outbreak.
A 2-year multicenter Veterans Administration (VA) retrospective cohort study published yesterday discovered that 5% of patients having outpatient surgeries received antimicrobial prophylaxis longer than 24 hours after surgery, with rates varying by procedure, facility type, and surgical specialty.
The latest data from the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) reveal stable levels of resistance to the currently recommended antibiotics for Neisseria gonorrhoeae, according to a report today from the European Centre for Disease Prevention and Control (ECDC). But high resistance to azithromycin threatens the effectiveness of the treatment regimen, ECDC officials warn.
An international team of scientists reported today in Eurosurveillance that the three extensively drug-resistant (XDR) gonorrhea cases identified in Australia and the United Kingdom in 2018 were caused by a single XDR clone.
Annual sentinel surveillance of Neisseria gonorrhea isolates in 25 European countries has found decreasing susceptibility to ceftriaxone, according to a study yesterday in BMC Infectious Diseases.
The drug, zoliflodacin, was highly effective in treating urogenital and rectal infections but not pharyngeal cases.
The arrival of the inevitable untreatable cases is being sped up by rising rates of gonorrhea and other STDs.
The new data mark a 4th straight year of "steep and sustained" increases.
